Accès ouvert
2023
conference-abstract
OpenAlex
Fabio Salvatore Macaluso, Mauro Grova, F Mocciaro, R Di Mitri et autres
Abstract Background Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of Ustekinumab (UST) as therapeutic option for the POR of CD is currently unknown Methods All consecutive CD patients with a baseline …
it
(code pays fourni par la source)
Accès ouvert
2021
conference-abstract
OpenAlex
Fabio Salvatore Macaluso, Maria Cappello, Federica Crispino, Mauro Grova et autres
Abstract Background The role of Vedolizumab (VDZ) as therapeutic option for the postoperative recurrence of Crohn’s disease (CD) following ileocolonic resection is currently unknown. We aimed to assess the effectiveness of VDZ in this setting. Methods All consecutive CD patients with an …
it
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Fabio Salvatore Macaluso, Walter Fries, Sara Renna, Anna Viola et autres
Abstract Background Biologic-naïve patients treated with Vedolizumab (VDZ) are largely underrepresented in real-world cohorts. We performed a multicentre, observational, cohort study on the effectiveness and safety of VDZ as treatment for Crohn’s disease (CD) and ulcerative colitis (UC) among biologic-naïve subjects. Methods …
it
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Giuseppe Costantino et autres
Abstract Background The efficacy of Ustekinumab (UST) on Crohn’s disease (CD) associated spondyloarthropathy (SpA) was evaluated neither in randomized controlled trials nor in real-world studies. Web-based data from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to …
it
(code pays fourni par la source)